THE ROLE OF PRIOR BALLOON AORTIC VALVULOPLASTY IN PATIENTS UNDERGOING TAVR: A PARTNER I SUBSTUDY ANALYSIS  by Doshi, Darshan et al.
TCT@ACC-i2: The Interventional Learning Pathway
A1730
JACC April 1, 2014
Volume 63, Issue 12
the role of Prior bAlloon Aortic VAlVuloPlAsty in PAtients unDergoing tAVr: A PArtner i 
substuDy AnAlysis
Poster Contributions
Hall C
Saturday, March 29, 2014, 10:00 a.m.-10:45 a.m.
Session Title: Valvular and Structural Heart Intervention
Abstract Category: 42. TCT@ACC-i2: Aortic Valve Disease
Presentation Number: 2101-284
Authors: Darshan Doshi, Mackram Eleid, Susheel Kodali, Kevin Greason, E. Murat Tuzcu, Ted Feldman, Ke Xu, Martin Leon, Charanjit Rihal, 
Columbia University Medical Center, New York, NY, USA, Mayo Clinic, Rochester, MN, USA
background: Balloon aortic valvuloplasty (BAV) has been utilized as a bridge to transcatheter aortic valve replacement (TAVR) in patients either 
too sick for TAVR or in whom there is uncertainty regarding the utility of TAVR. However, the characteristics and outcomes following TAVR in patients 
with a prior BAV are unknown.
Methods: All patients undergoing TAVR from the randomized PARTNER trial, as well as the non-randomized, continued access registry, were 
dichotomized into those with and without prior BAV. Baseline demographics, echocardiographic parameters, and long-term outcomes were assessed.
results: Of 2474 patients enrolled, 558 underwent BAV prior to TAVR. BAV patients were more likely to be women (51% vs. 46%, p=0.04) and 
older in age (85 vs. 84, p=0.01), including those 90 years or older (24% vs. 19%, p=0.01). BAV patients had higher STS risk scores (12.2 vs. 11.2, 
p<0.01), smaller BMI (26 vs. 27, p<0.01), greater prevalence of pulmonary hypertension (44% vs. 37%, p<0.01), and more NYHA class III and IV 
symptoms (96% vs. 94%, p=0.04). Patients with BAV had reduced ejection fraction (51% vs. 52%, p=0.01) but higher aortic valve area (0.65 cm2 vs. 
0.62 cm2, p=0.02). At 30 days, there was no difference in all-cause mortality (6.5% with BAV vs. 6.1% without BAV, p=0.73) or cardiovascular (CV) 
mortality (4.3% with BAV vs. 4.4% without BAV, p=0.93). By 1-year, there was greater out of hospital death in the BAV group (21% vs. 17%, HR 1.26, 
95% CI 1.02-1.57, p=0.03), and a trend towards higher all-cause mortality (26% vs. 22%, p=0.059). At 2-years, in the randomized group, there was 
greater CV mortality in those with BAV (24% vs. 13%, HR 2.0, CI 1.12-3.55, p=0.02) and a trend towards higher all-cause mortality (48% vs. 35%, 
p=0.05). 2-year outcomes in the non-randomized, continued access registry are pending adjudication but will be included in the final presentation.
conclusions: Patients that underwent BAV prior to TAVR had higher STS risk scores and greater prevalence of co-morbidities compared to those 
without BAV prior to TAVR. Although patients with prior BAV have similar short-term mortality rates compared to those that did not undergo BAV, out 
of hospital and long-term mortality are higher in this group.
